TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: A Phase 3, Double Blind, Placebo Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Brief Summary: To evaluate the efficacy and safety of lumacaftor in combination with ivacaftor in subjects aged 6 Through 11 years with cystic fibrosis (CF), homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation


Options:
A: Variations in the Sino-nasal-outcome test SNOT-20 adapt CF (primary nasal parameters: obstruction of nasal breathing, sneeze stimulus, permanent nose running, thick-mucous nasal discharge, earaches) (day 1, 29, 57 and 85)
B: Changes in the Sino-nasal-outcome test SNOT-20 adapt CF (days 1, 29, 57 and 85)
C: Number of Subjects With Adverse Events (Combined Part 1 and Part 2) (Baseline to Follow-up); Number of Adverse Events (Combined Part 1 and Part 2) (Baseline to Follow-up)
D: Absolute Change From Baseline in Lung Clearance Index 2.5 (LCI2.5) Through Week 24 (Baseline, Through Week 24)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Is MyPlate.Gov Approach to Helping Overweight Patients Lose Weight More Patient-centered?
Brief Summary: Investigators from the University of California-Los Angeles (UCLA) and The Children's Clinic of Long Beach (TCC) are conducting a randomized, controlled comparative effectiveness trial of two government-sanctioned behavior change approaches to weight control with TCC's obese patients. The first approach is the calorie-counting calorie restriction (CC) approach used in the Diabetes Prevention Program. The second approach is the high-satiation/high-satiety approach represented by MyPlate.gov. The MyPlate nutritional goal is to double patient fruit and vegetable intake, legume intake, and whole grain intake. Both conditions stipulate 150 minutes of moderate physical activity a week. Study participants will be 300 of TCC's obese patients, 76% of whom are expected to be Latino, 13% African American and 11% Other Ethnicities.

The interventions will be implemented by trained community lifestyle change coaches with brief support from clinicians. The interventions will include two home visits, two group education sessions and seven telephone behavior change coaching sessions.

Compared to the CC approach, the MyPlate approach is hypothesized to yield better 12 months patient-centered outcomes, particularly self-reported satiety.


Options:
A: Knowledge about Living Kidney Donation (3 weeks)
B: Change of Activities of Daily Life (ADL) (change from baseline at 6 months and 1 year); Change of Sense of Coherence (KASAM) (change from basline at 6 months and 1 year)
C: Patient-centered Outcome Measure = Self-reported Hunger (12 months follow-up); Medical Outcome Measure = Body Weight (12 months follow-up); Meal Satisfaction Yesterday (12 months follow-up); Feeling Full After Last Meal Yesterday (12 months follow-up)
D: Efficacy of Motivation and Problem Solving (MAPS) in Cancer Risk Reduction (6 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Ridge Preservation Following Tooth Extraction Using Mineralized Freeze-Dried Bone Allograft Compared to PUROS Mineralized Bone Allograft
Brief Summary: The study is a 2-arm, parallel-design, randomized, prospective clinical trial designed to examine histologic wound healing following ridge preservation using bone allograft that has been prepared by either freeze-drying or via a non-freeze-dried solvent process.This entire protocol involves procedures that are standard care. All materials are FDA-approved materials being used in an FDA-approved manner. The test group subjects will have extraction sockets grafted with a cancellous non-freeze-dried bone allograft (called PUROS graft). This test group will be compared to an active control group using cancellous freeze-dried bone allograft (called FDBA). The null hypothesis is that there will be no significant difference in formation of new vital bone between treatment groups (primary outcome).

Each subject will provide a single non-molar tooth site for study treatment. After tooth extraction, the graft material will be placed and covered by a resorbable collagen membrane. Following 3 months of healing, the dental implant will be place, at which time a core of bone will be removed from the site as part of the preparation for the implant. The core biopsy will then be evaluated for the primary histologic outcome of % vital bone formation and secondary histologic outcome of % residual graft material.


Options:
A: % Vital Bone Formation (Histological) (18-20 weeks after ridge preservation)
B: % Vital Bone Formation (Histological) (3 months after ridge preservation)
C: Radiographic Bone Changes (3 months after tooth extraction)
D: Change in Bone Gain or Loss in Millimeters (Buccopalatal) (From Baseline to 12 weeks); Change in Bone Gain or Loss in Millimeters (Mesiodistal) (From Baseline to 12 weeks); Change in Bone Gain or Loss in Millimeters (Stent to Apex) (From Baseline to 12 weeks); Radiographic Bone Changes (From Baseline to 12 weeks); New Bone Formation (From Baseline to 12 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia
Brief Summary: Acute respiratory infections are the fourth cause of hospitalization in elderly. Various studies have examined the impact of hospitalization in patients with respiratory pathology, showing the need of interventions in order to reduce the impact of hospitalization. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.


Options:
A: Glittre test (up to 9 months)
B: The Primary Outcome Variable for This Study Will be the Short Form of the Continuous Scale Physical Functional Performance Test (CS-PFP) Called the PFP-10 (1 month)
C: Muscle strength (Participants will be followed for the duration of hospital stay, an expected average of 8 days); Exercise capacity (Participants will be followed for the duration of hospital stay, an expected average of 8 days)
D: Change in 30-s chair stand performance (Baseline (admission to hospital), within 3 days of discharge, and 12 weeks after discharge)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Effects of a Physiotherapy Program in Patients Hospitalized Due to Pneumonia
Brief Summary: Acute respiratory infections are the fourth cause of hospitalization in elderly. Various studies have examined the impact of hospitalization in patients with respiratory pathology, showing the need of interventions in order to reduce the impact of hospitalization. The objective of this study is to examine whether a physical therapy intervention can reduce impairment in patients hospitalized due to pneumonia.


Options:
A: Change in adventitious lung sounds (24 hours after hospital presentation (baseline) and 3 weeks after intervention)
B: Length of Hospital Stay (End of hospital stay); Time to Clinical Stability (Daily for the duration of the hospital stay); Symptomatic and Functional Recovery Score (14, 30, and 60 days post-admission)
C: Glittre test (up to 9 months)
D: Muscle strength (Participants will be followed for the duration of hospital stay, an expected average of 8 days); Exercise capacity (Participants will be followed for the duration of hospital stay, an expected average of 8 days)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Southwest Health Extension Partnership to Enhance Research Dissemination
Brief Summary: Heart disease and strokes cause one in three deaths reported each year in the United States. Primary care practices need to implement new research findings that help decrease patients' risk for heart disease and stroke. This project will help to build primary care practice capacity for quality improvement and change management in small and medium size primary care practices in Colorado and New Mexico. This project will also help practices implement patient-centered outcomes research findings.


Options:
A: Change of documentation of aspirin therapy in patients with ischemic vascular disease. (Baseline, 3, 6, 9, 12, and 15 months from baseline); Change of documentation of blood pressure in patients with a diagnosis of hypertension. (Baseline, 3, 6, 9, 12, and 15 months from baseline); Change of documentation of blood pressure in patients with adequately controlled blood pressure. (Baseline, 3, 6, 9, 12, and 15 months from baseline); Change of documentation of fasting LDL in patients with a fasting LDL at or below the LDL goal. (Baseline, 3, 6, 9, 12, and 15 months from baseline); Change of documentation of patients who had a fasting LDL test performed and prescribed a statin based on risk. (Baseline, 3, 6, 9, 12, and 15 months from baseline); Change of documentation of patients screened about tobacco use. (Baseline, 3, 6, 9, 12, and 15 months from baseline)
B: Reach (Entire 6 month early or delayed implementation phase); Effectiveness - Ask (6 month early implementation phase); Effectiveness - Goal Setting (6 month early implementation phase); Effectiveness - Assistance (6 month early implementation phase); Effectiveness - Referred (6 month early implementation phase)
C: Change in uptake of shared decision-making from the patients' perspective (All clinics: baseline, 8 months, 16 months, 24 months)
D: Change in Emergency Department Visits + Hospital Days (Pre-Intervention (09/01/2012 to 03/09/2014); Post-Intervention (03/10/2014-09/30/2015)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial
Brief Summary: A randomised controlled trial assessing the efficacy of single versus repeated dose of vaginal misoprostol for the treatment of early pregnancy failure.


Options:
A: Complete abortion without recourse to surgical intervention. (follow up visit 7 days after initial treatment)
B: The number of patients with complete miscarriage at 1 week. (1 week)
C: Complete evacuation (six weeks after initial treatment)
D: Complete abortion (Endometrial thickness of less than 15 mm, as assessed by trans-vaginal ultrasound.) (Day 8 from first misoprostol dose)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial
Brief Summary: A randomised controlled trial assessing the efficacy of single versus repeated dose of vaginal misoprostol for the treatment of early pregnancy failure.


Options:
A: Complete abortion (Endometrial thickness of less than 15 mm, as assessed by trans-vaginal ultrasound.) (Day 8 from first misoprostol dose)
B: Success rate of abortion (24 hours); Interval to abortion (24 hours)
C: Complete abortion without recourse to surgical intervention (follow up visit 7 days after initial treatment)
D: Complete abortion without recourse to surgical intervention. (follow up visit 7 days after initial treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Comparison of Single and Repeated Dose of Vaginal Misoprostol for the Treatment of Early Pregnancy Failure - a Randomized Clinical Trial
Brief Summary: A randomised controlled trial assessing the efficacy of single versus repeated dose of vaginal misoprostol for the treatment of early pregnancy failure.


Options:
A: Complete evacuation (six weeks after initial treatment)
B: complete abortion rate (5 weeks after treatment)
C: Ongoing pregnancy rates (1-2 weeks)
D: Complete abortion (Endometrial thickness of less than 15 mm, as assessed by trans-vaginal ultrasound.) (Day 8 from first misoprostol dose)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: Long-term Smoking Abstinence (30-day Point Prevalence Abstinence) (6 months after enrollment)
B: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
C: Child Urine Cotinine (up to 12 months); Parent-reported Second-hand Smoke Exposure in Cigarettes Per Day From All Sources (up to 12 months)
D: Self-reported, Prolonged Abstinence From Smoking Between a Quit Date and 6 Months Afterwards. (6 months from participant's quit date)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: 4-week continuous quit rate (CQR) at Weeks 4-7 and 9-12 .
B: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.
C: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
D: Rating of urges to smoke one week after the target quit date assessed by Mood and Physical Symptoms Scale (1 week)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: Change in Flow mediated Dilation (FMD) between the TC group and the EC-nicotine and EC-nicotine free groups (Baseline and 1 month)
B: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
C: smoking status (baseline, 3, 6, 12, and 18 months follow-up); commitment to abstinence (baseline, 3, 6, 12, and 18 months); quit attempts (3, 6, 12, and 18 months follow-up)
D: reducers (week-24 from baseline)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: Continuous smoking abstinence rate (Weeks 9 to 12)
B: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
C: 4 week Continuous Quit Rate ( 4 week CQR ) for Weeks 9 -12.
D: to assess the continuous abstinence from tobacco smoking at every visit during the last four weeks of treatment through direct inquiry of patients; exhaled carbon monoxide testing; and plasma cotinine measurements

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: verified abstinence 6 months (6 months)
B: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
C: Number of cigarettes smoked per day (End of 6 week intervention)
D: Number of participants who achieve 50% reduction in Cigarettes Per Day (CPD) (12 weeks); Average change in score on the mMRC Dyspnea Scale (Baseline, 12 weeks)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
B: Sustained 50% Reduction in the Number of Cig/Day at Week-24 From Baseline (Reducers) (number of cigarettes/day as assessed at week 24)
C: Intervention effect on Flow-mediated dilatation (FMD) assessed via ultrasound (%FMD). (6 months following quit day.)
D: Traditional smoking cessation rate (5 years); Change from baseline in the number of traditional cigarette smoked (6, 12, 24, 36 and 60 months.)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: Percentage of Participants Who Abstained From Smoking at 10 and 30 Weeks Post Quit Day (End of treatment (10 weeks post quit day) and 30-week follow-up)
B: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
C: Point prevalence abstinence at 6 months (6 months after beginning treatment)
D: Point-prevalence abstinence (1 year); Change from baseline in depressive symptoms on the Beck Depression Inventory-II (BDI-II) (1 year); Change from baseline in depressive symptoms on the Hamilton Depression Rating Scale (1 year)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: New Hampshire Medicaid Wellness Incentive Program
Brief Summary: The New Hampshire Medicaid Wellness Incentive Program (WIP) will address both the health disparity and increased costs by providing incentivized health promotion programs to overweight or obese and/or tobacco-smoking Medicaid beneficiaries receiving services at New Hampshire's 10 regional Community Mental Health Centers (CMHCs).


Options:
A: smoking cessation (52 weeks)
B: Acute electronic cigarette vaping effects on arterial stiffness. (7 minutes); Acute electronic cigarette vaping effects on endothelial integrity. (7 minutes); Chronic electronic cigarette vaping effects on arterial stiffness. (1 month); Chronic electronic cigarette vaping effects on endothelial integrity. (1 month); Chronic electronic cigarette vaping effects on platelet aggregation. (1 month); Chronic electronic cigarette vaping effects on high-shear stress-dependent platelet function. (1 month)
C: Change in Weight (Baseline, 3 months, 6 months, 9 months, 12 months and 1 year post program follow up); Change in the 6 minute walk test (Baseline, 3 months, 6 monhts, 9 months, 12 months, and 1 year post program completion follow up); Change in Days of Abstinence-Timeline follow back interview for tobacco smokers (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up); Change in Carbon Monoxide Level (Baseline, 3 months, 6 months, 9 months, 12 months, and 1 year post program completion follow up)
D: Endothelial dysfunction (up to 24 weeks); Oxidative stress (up to 24 weeks)

Answer: C